Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Cash from Operations: 2016-2024

Historic Cash from Operations for Organogenesis Holdings (ORGO) over the last 9 years, with Dec 2024 value amounting to $14.2 million.

  • Organogenesis Holdings' Cash from Operations fell 64.59% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.8 million, marking a year-over-year decrease of 379.38%. This contributed to the annual value of $14.2 million for FY2024, which is 54.04% down from last year.
  • Latest data reveals that Organogenesis Holdings reported Cash from Operations of $14.2 million as of FY2024, which was down 54.04% from $30.9 million recorded in FY2023.
  • In the past 5 years, Organogenesis Holdings' Cash from Operations ranged from a high of $62.0 million in FY2021 and a low of $5.5 million during FY2020.
  • Moreover, its 3-year median value for Cash from Operations was $24.9 million (2022), whereas its average is $23.3 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first surged by 1,033.88% in 2021, then slumped by 59.89% in 2022.
  • Organogenesis Holdings' Cash from Operations (Yearly) stood at $5.5 million in 2020, then soared by 1,033.88% to $62.0 million in 2021, then crashed by 59.89% to $24.9 million in 2022, then grew by 24.37% to $30.9 million in 2023, then plummeted by 54.04% to $14.2 million in 2024.